肝肺综合征（HPS）为晚期肝脏疾病的肺脏血管紊乱性疾病，与肺内血管扩张引起的血氧不足有关。无论肝病严重程度，HPS可以独立增加死亡率。肝移植可改善 HPS生存率。我们评估了从 1986年至2010年梅奥诊所就诊的106例 HPS患者。使用Kaplan-Meier进行生存评估。共有49例患者进行了肝脏移植。根据诊断HPS时基线PaO2划分的移植后生存率(1,3,5,10年)并无差异。2002年 1月 1日之后进行移植的患者(n=28)1,3,5年生存率 (92%,88%和 88%)优于之前移植患者(n=21,71%,67% 和 67%)。HPS肝移植后长期结局较好，且生存率得到较好改善，但生存率与HPS诊断时的PaO2水平无相关性。
吉林大学第一医院肝病科 尹程程 摘译
本文首次发表于[Hepatology,013, 57(6):2427-35]2
Hepatopulmonary syndrome: Favorable outcomes in the MELD exception era.
Hepatopulmonary syndrome (HPS) is a pulmonary vascular disorder occurring as a consequence of advanced liver disease, characterized by hypoxemia due to intrapulmonary vascular dilatations. HPS independently increases mortality, regardless of the cause or severity of liver disease. Liver transplantation (LT) improves survival in HPS. We evaluated 106 HPS(Hepatopulmonary syndrome )patients at the Mayo Clinic from 1986 through 2010. Survival was assessed using Kaplan-Meier methodology. LT was accomplished in 49 HPS (Hepatopulmonary syndrome )patients.Post-LT survival (1, 3, 5, and 10 years) did not differ between groups based on baseline partial pressure of arterial oxygen (PaO2 ) obtained at the time of HPS(Hepatopulmonary syndrome ) diagnosis. Improvements in overall survival at 1, 3, and 5 years post-LT in those HPS patients transplanted after January 1 2002 (n = 28) (92%, 88%, and 88%, respectively) as compared with those transplanted prior to that time (n = 21) (71%, 67%, and 67%, respectively) did not reach statistical significance (5-year P = 0.09).Long-term outcome after LT in HPS (Hepatopulmonary syndrome ) is favorable, Survival after LT was not associated with PaO2 levels at the time of HPS diagnosis.
